⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754996 | 0.98 | MAPT (0.54) | — | |
| SCHEMBL834166 | 0.92 | — | — | |
| SCHEMBL833960 | 0.81 | — | — | |
| SCHEMBL1030118 | 0.81 | — | — | |
| SCHEMBL1031233 | 0.81 | — | — | |
| SCHEMBL10829607 | 0.75 | — | — | |
| SCHEMBL4848656 | 0.75 | — | — | |
| SCHEMBL366803 | 0.74 | MAPT (0.43) | — | |
| SCHEMBL7911220 | 0.74 | MAPT (0.43) | — | |
| SCHEMBL8598283 | 0.73 | MAPT (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848832-B | Application of fluorine-containing compound modified cationic polymer as drug carrier and preparation method thereof | 苏州大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-111892667-B | Application of fluorine-containing compound modified cationic polymer in preparation of medical cosmetic and health care products | 苏州大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-111848831-B | Application of fluorine-containing compound modified cationic polymer in preparation of vaccine medicine | 苏州大学 | 2023-06-13 | — | — | CN | disclosed |
| US-10439252-B2 | Electrolyte solution for electrochemical device, and electrochemical device | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-08 | — | — | US | disclosed |
| EP-3149017-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Idenix Pharmaceuticals LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150364792-A1 | ELECTROLYTE SOLUTION FOR ELECTROCHEMICAL DEVICE, AND ELECTROCHEMICAL DEVICE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| WO-2015181624-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS, INC (US) | 2015-12-03 | — | — | WO | disclosed |
| EP-2755985-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| WO-2013039855-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2007025043-A2 | SEVEN-MEMBERED RING NUCLEOSIDES | IDENIX PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1633766-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Pharmasset, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1576138-A2 | 2-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | Idenix (Cayman) Limited (KY) | 2005-09-21 | — | — | EP | disclosed |
| EP-1536804-A2 | 2'-C-METHYL-3'-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-06-08 | — | — | EP | disclosed |
| EP-1525209-A2 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | Idenix (Cayman) Limited (KY) | 2005-04-27 | — | — | EP | disclosed |
| WO-2005003147-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | disclosed |
| US-20040077587-A1 | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | IDENIX PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004002422-A2 | 2’-C-METHYL-3’-O-L-VALINE ESTER RIBOFURANOSYL CYTIDINE FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004003000-A2 | 1’-, 2'- AND 3'- MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX (CAYMAN) LIMITED (KY) | 2004-01-08 | — | — | WO | disclosed |